This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
LLY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
LLY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.
The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon
by Tirthankar Chakraborty
The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon
Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Eli Lilly (LLY) and BNY Mellon (BK).
J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay
by Zacks Equity Research
The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.
Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Eli Lilly (LLY) and Broadcom (AVGO).
Pfizer to Defer Price Increases After Discussion With Trump
by Zacks Equity Research
Pfizer, Inc. (PFE) to defer its recent price increases of several prescription drugs after discussion with Trump.
Biogen's Alzheimer Disease Candidate Succeeds in Phase II
by Zacks Equity Research
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Is Pfizer's Price Hike an Effect of Drug Policy on Sector?
by Zacks Equity Research
Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.
Merck's Keytruda Gets Priority Review in Difficult Lung Cancer
by Zacks Equity Research
Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.
Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study
by Zacks Equity Research
Lilly (LLY) posts positive top-line results from a second phase III study on Taltz for the treatment of Ankylosing Spondylitis (AS).
Will a Trade War With China Wreak Havoc in US Healthcare?
by Nitish Marwah
It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.
The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern
Top Research Reports for Amazon, Intel & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Intel (INTC) and Eli Lilly (LLY).
Merck's Keytruda Under FDA Review for Advanced Melanoma
by Zacks Equity Research
Merck (MRK) announces acceptance of its sBLA for Keytruda by the FDA for the treatment of patients with high-risk stage III melanoma.
Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies
by Zacks Equity Research
Lilly's (LLY) Jardiance and Humulin, being evaluated in separate phase III studies, meet primary endpoint of reduction in blood sugar level.
Merck (MRK) Presents New Data from Januvia Diabetes Studies
by Zacks Equity Research
Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.
Lilly Wins Favorable Ruling From U.S. Court in Alimta Row
by Zacks Equity Research
Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.
Merck (MRK) Stock Up So Far This Year on Keytruda Strength
by Zacks Equity Research
Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
Incyte (INCY) Announces Positive Results on Jakafi for GVHD
by Zacks Equity Research
Incyte (INCY) reports positive results on Jakafi from the REACH trial for the indication of acute GVHD. The company plans to file a sNDA for the drug in the third quarter.
Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study
by Zacks Equity Research
Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.
LLY vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LLY vs. NVO: Which Stock Is the Better Value Option?
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is Eli Lilly and Company (LLY) Outperforming Other Medical Stocks This Year?